Galectin Therapeutics (GALT) Enterprise Value (2010 - 2026)

Galectin Therapeutics' Enterprise Value history runs 17 years deep, the most recent figure standing at -$14.1 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 89.75% year-over-year to -$14.1 million; the TTM figure through Mar 2026 stood at -$14.1 million (down 89.75% YoY), while the FY2025 annual figure was -$17.7 million, down 17.2% from the prior year.
• Enterprise Value was -$14.1 million for Q1 2026 at Galectin Therapeutics, up from -$17.7 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$7.4 million in Q1 2025 to a low of -$31.6 million in Q1 2022.
• Historically, Enterprise Value has averaged -$19.3 million across 5 years, with a median of -$18.0 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Enterprise Value surged 68.45% in 2025, then slumped 89.75% in 2026.
• A 5-year view of Enterprise Value shows it stood at -$18.6 million in 2022, then tumbled by 38.02% to -$25.7 million in 2023, then soared by 41.08% to -$15.1 million in 2024, then dropped by 17.2% to -$17.7 million in 2025, then grew by 20.43% to -$14.1 million in 2026.
• The last three Enterprise Value figures came in at -$14.1 million (Q1 2026), -$17.7 million (Q4 2025), and -$11.5 million (Q3 2025), per Business Quant data.